FULL SUPPLEMENT: Nordic European Cutaneous Oncodermatology Management (Necom) 5: A Practical Algorithm for the Treatment And Supportive Management of Cutaneous Adverse Events in Patients Receiving Targeted Therapy for Cancer

Although cancer incidences seemingly continue to rise, ongoing advancements in cancer therapy have simultaneously contributed to improved survival. Nordic survival studies from the past decades have shown clear trends of improved 1- and 5-year survival across different cancer types. Between 2018 and 2022, the relative 5-year cancer survival percentage of males and females in the Nordic countries was between 70 to 78% and 73 to 76%, respectively.1 In anticipation of longer life spans with earlier diagnosis and improved treatment approaches, more patients will come upon a cancer diagnosis and treatment in their lifetime.